What Is 7-OH? The Emerging Opioid Threat Addiction Professionals Need to Understand in 2026

What Is 7-OH? The Emerging Opioid Threat Addiction Professionals Need to Understand in 2026

By Benjamin Zohar, NCACIP — Nationally Certified Advanced Clinical Intervention Professional | ISSUP New York Moderator
Medical Review: Brandon McNally, RN
Published: March 2026 | Last Updated: March 2026

Key Takeaways

• 7-hydroxymitragynine (7-OH) is a potent opioid-like compound derived from the kratom plant that binds to mu-opioid receptors with 14 to 22 times the affinity of morphine, according to Johns Hopkins University researchers.
• The FDA recommended Schedule I classification for concentrated 7-OH products in July 2025, and the DEA is currently reviewing whether to proceed with scheduling — a decision that could come in 2026.
• Fatal overdoses linked to concentrated 7-OH products have been confirmed in Los Angeles County, where three otherwise healthy adults aged 18 to 40 died, and poison control calls related to kratom and 7-OH surged to 192 in Texas alone by August 2025.
• 7-OH withdrawal can last significantly longer than traditional opioid withdrawal — potentially up to three months — complicating treatment and increasing relapse risk.
• Products containing concentrated 7-OH are widely sold in gas stations, smoke shops, and online as gummies, tablets, drinks, and candy, often marketed to young adults with no dosing guidance or safety warnings.

Understanding 7-OH: What Addiction Professionals Need to Know

7-hydroxymitragynine, commonly referred to as 7-OH, is a terpenoid indole alkaloid found in trace amounts in the leaves of Mitragyna speciosa, the tropical tree known as kratom. First described in scientific literature in 1994, 7-OH occurs naturally at concentrations typically below 2% of the total alkaloid content in kratom leaves. It is produced in the human body as a metabolite of mitragynine — kratom's primary alkaloid — through hepatic oxidation by cytochrome P450 3A enzymes.

What makes 7-OH the subject of urgent regulatory attention in 2025 and 2026 is not the compound as it exists in natural kratom leaf products. The concern centers on concentrated, semi-synthetic, and synthetic 7-OH products that have flooded the U.S. consumer market since late 2023. These products can contain up to 98% 7-OH by concentration, according to the Texas Department of State Health Services — a dramatic departure from the trace amounts found in whole-leaf kratom.

As FDA Commissioner Dr. Marty Makary stated during a July 2025 press conference: the agency is specifically targeting concentrated synthetic 7-OH, not natural kratom leaf products. This distinction is critical for addiction professionals who may encounter clients using either traditional kratom or these far more potent 7-OH derivatives.

How Potent Is 7-OH Compared to Morphine and Other Opioids?

The potency of 7-hydroxymitragynine is what separates it from traditional kratom and places it firmly in the category of substances requiring clinical attention. Research published by Johns Hopkins University School of Medicine describes 7-OH as a highly selective partial mu-opioid receptor agonist with binding affinity between 14 and 22 times greater than morphine. Other published estimates have placed the analgesic potency at approximately 13 times that of morphine.

By comparison, mitragynine — kratom's most abundant alkaloid — has substantially lower potency at opioid receptors and has shown lower abuse potential in animal models. A pivotal 2019 study published in Addiction Biology found that 7-hydroxymitragynine, but not mitragynine, substituted for morphine self-administration in rats in a dose-dependent manner, indicating meaningful abuse liability. Critically, the study also found that exposure to 7-OH subsequently increased morphine self-administration, raising concerns about gateway effects.

Dr. Christopher McCurdy, a professor of medicinal chemistry at the University of Florida College of Pharmacy, has compared the marketing of concentrated 7-OH products to the early promotion of OxyContin in the 1990s. His laboratory research on rodents has demonstrated that 7-OH is as highly addictive as prescription opioids, and that its respiratory depressive effects and abuse potential can be reversed with naloxone (Narcan) — a hallmark characteristic of opioid agonism.

How 7-OH Is Sold: The "Gas Station Opioid" Problem

Concentrated 7-OH products are widely available across the United States in forms that are virtually indistinguishable from over-the-counter supplements or candy. The Los Angeles County Department of Public Health noted in a September 2025 health alert that these products are sold in gas stations, smoke shops, and online venues, often labeled with vague terms like "plant alkaloids" or simply "alkaloid" rather than clearly identifying the active ingredient.

Common product forms include:

• Tablets: Typically ranging from 5 mg to 22 mg per tablet. Purple tablets commonly contain 20–22 mg; green tablets contain 5–10 mg. Many are scored for splitting.
• Gummies and candy: Designed with appealing colors and flavors that may attract younger consumers. Colorado enacted legislation specifically prohibiting kratom products from being sold as candy or in forms that appeal to children.
• Drink shots and mixes: Pocket-sized liquid vials marketed alongside energy drinks and supplements.
• Vape products: Offering nearly immediate onset of effects through inhalation.

In July 2025, the FDA issued warning letters to seven companies for illegally marketing concentrated 7-OH products as dietary supplements, foods, or unapproved drugs. The agency emphasized that 7-OH cannot be lawfully sold as a dietary supplement and cannot be legally added to conventional foods. There are no FDA-approved drug products containing 7-OH.

Confirmed Deaths and Rising Emergency Department Visits

The public health data surrounding concentrated 7-OH products has escalated rapidly:

• Los Angeles County (September 2025): The County Medical Examiner identified three fatal overdoses in residents aged 18 to 40. All three individuals were described as otherwise healthy, with no other substances identified as substantively contributing to their deaths. Alcohol was present in all cases. 7-OH was identified as the primary cause of death.
• Texas (August 2025): The Texas Poison Center Network received 192 reports of kratom/7-OH exposures by late August 2025, compared to 107 for all of 2024 and 122 for all of 2023. Of 19 patients exposed specifically to concentrated 7-OH products, 11 required treatment at healthcare facilities.
• Pennsylvania: Reports indicate that 14 patients required mechanical ventilation (breathing machines) due to severe respiratory distress following 7-OH exposure.
• Washington State: The Washington Poison Center reported that poison center kratom exposures surged to 1,800 by early August 2025, with approximately one-third of calls specifically involving 7-OH extracts. This represented a dramatic increase from the 330 to 1,400 annual calls seen between 2015 and 2024.

These incidents underscore a critical clinical reality: high doses of 7-OH, especially when combined with alcohol or other sedatives, can cause severe respiratory depression and death. The Los Angeles County Department of Public Health confirmed that naloxone can reverse 7-OH toxicity, though repeated doses may be required.

 

7-OH Addiction: What the Science Says About Dependence Risk

For a deeper explanation of treatment approaches, see this guide on kratom addiction treatment.

Multiple lines of evidence point to significant addiction potential for concentrated 7-OH products:

Researchers at Johns Hopkins University School of Medicine published a letter in The Society for the Study of Addiction journal warning that chronic 7-hydroxymitragynine product use could result in opioid-like physical dependence and possibly addiction. Lead researcher Dr. Kirsten Smith, an assistant professor of psychiatry and behavioral sciences at Johns Hopkins, has proposed that patients using 7-OH products should be evaluated for both Kratom Use Disorder (KUD) and Opioid Use Disorder (OUD), given 7-OH's potent mu-opioid receptor agonism.

Animal studies have demonstrated that 7-OH maintains intravenous self-administration in rats — a gold-standard measure of abuse liability — and that its reinforcing effects are mediated primarily through mu-opioid receptors. For a deeper look at the relationship between kratom use and dependence, see this guide on kratom addiction. The University of Florida's Dr. McCurdy has noted that the hallmark sign of an opioid is that its effects can be reversed with Narcan, which is the case with 7-OH.

Clinically, users report rapid tolerance development, requiring escalating doses to achieve the same effects. Dr. Smith has noted that the effects of 7-OH may wear off quickly, potentially leading users to re-dose sooner — a pattern that increases dependence risk.

7-OH Withdrawal: Duration, Symptoms, and Treatment Challenges

7-OH withdrawal represents one of the most clinically significant challenges for addiction treatment professionals encountering this substance. Unlike traditional opioid withdrawal, which typically resolves within approximately one week, kratom and 7-OH withdrawal can persist for up to three months after discontinuation, according to researchers at the University of Illinois at Chicago College of Pharmacy.

The withdrawal timeline generally follows three phases:

Acute Phase (Days 1–7): The most severe physical symptoms, including muscle pain, nausea, vomiting, insomnia, anxiety, sweating, and agitation. These symptoms closely mirror opioid withdrawal.

Sub-Acute Phase (Weeks 1–3): Persistent fatigue, mood instability, poor concentration, irritability, and ongoing sleep disturbances.

Post-Acute Withdrawal Syndrome (PAWS): In some individuals, emotional instability, cognitive difficulties, anhedonia, and cravings can persist for weeks to months, significantly increasing relapse risk.

Regarding pharmacological treatment, buprenorphine and buprenorphine-naloxone (Suboxone) have been used off-label for kratom and 7-OH withdrawal management. The Washington Poison Center has described a case in which a patient experiencing 7-OH toxicity was successfully initiated on buprenorphine/naloxone in the emergency department, with resolution of symptoms. The patient was prescribed a 14-day course and referred for follow-up care.

This extended withdrawal timeline has direct implications for treatment planning: standard 7-day detox protocols may be insufficient for individuals with significant 7-OH dependence, and longer-term residential or intensive outpatient programming should be considered.

Federal Regulatory Action: The Path Toward Schedule I Classification

The regulatory landscape for 7-OH shifted dramatically in mid-2025:

July 15, 2025: The FDA issued warning letters to seven companies for illegally marketing concentrated 7-OH products.

July 29, 2025: In a joint press conference, the FDA formally recommended to the DEA that 7-hydroxymitragynine be classified as a Schedule I controlled substance under the Controlled Substances Act. HHS Secretary Robert F. Kennedy Jr. described the action as "a critical step in the fight against opioid addiction." FDA Commissioner Dr. Makary warned that concentrated, synthetic 7-OH "may be the fourth wave of the opioid epidemic."

The DEA is now reviewing the FDA's recommendation. The scheduling process typically involves a public comment period before any final action. Historically, the DEA has used a two-step approach — first issuing a temporary scheduling order, then proceeding to permanent scheduling through formal rulemaking. However, legal analysts have noted that the DEA could pursue either pathway. If emergency scheduling is pursued, the action would take effect quickly. Permanent scheduling through formal rulemaking could take 18 to 24 months.

Notably, this is not the first time federal authorities have targeted kratom alkaloids. In 2016, the DEA announced intent to place both mitragynine and 7-hydroxymitragynine into Schedule I but withdrew the proposal after significant public opposition. The current action differs in that it specifically targets concentrated 7-OH products while explicitly distinguishing them from natural kratom leaf.

State-by-State Legal Status of 7-OH (Current as of March 2026)

While federal scheduling remains pending, state-level action has accelerated:

States with full kratom and 7-OH bans: Alabama, Arkansas, Indiana, Vermont, and Wisconsin have prohibited kratom and all its alkaloids, including 7-OH.

Louisiana: As of August 1, 2025, Louisiana added both 7-OH and mitragynine to its Schedule I controlled substances list.

Florida: On August 13, 2025, Florida Attorney General James Uthmeier filed an emergency rule classifying concentrated 7-OH as a Schedule I controlled substance, effective immediately. Florida became the first state to specifically ban 7-OH products as distinct from traditional kratom. The emergency rule is effective for one year, and Uthmeier announced plans to pursue permanent legislation during the 2026 legislative session. The rule has faced a legal challenge from industry groups.

California: On October 24, 2025, the California Department of Public Health issued a statewide consumer warning declaring that foods, dietary supplements, and drugs containing kratom or 7-OH are dangerous and illegal to sell or manufacture in California.

Mississippi and Colorado: Both states banned synthetic 7-OH in 2025.

Rhode Island: After previously banning kratom, Rhode Island became the first state to reverse its ban, creating a regulatory framework for kratom similar to its cannabis program, to take effect in April 2026.

Additional state activity: Multiple states including Ohio, Virginia, and Arizona have enacted or are pursuing restrictions on synthetic or concentrated 7-OH products. At least seven states considered kratom-related legislation in 2025, including proposals for bans, age restrictions, and labeling requirements.

Addiction professionals should check current local and state regulations, as this legal landscape is evolving rapidly.

Clinical Implications for Addiction Treatment Professionals

The emergence of concentrated 7-OH products presents several challenges for treatment providers, intervention professionals, and clinical staff:

Assessment: As recommended by Johns Hopkins researchers, clinicians should screen patients for use of kratom-derived products across four distinct subtypes: whole-leaf kratom, kratom extracts, concentrated 7-OH products, and combination products. Brand names and product forms should be documented, as the clinical profile differs dramatically between these categories.

Testing: Standard drug panels — including 5-panel, 10-panel, and 12-panel tests — do not screen for kratom alkaloids or 7-OH. Specialized testing can detect mitragynine, which remains detectable in blood for approximately 12 days. However, testing specifically for 7-OH requires specialty laboratory analysis and provides primarily qualitative rather than quantitative results, as 7-OH is unstable in biological samples.

Treatment Planning: Given the extended withdrawal timeline and opioid-like dependence profile, treatment providers should consider longer detoxification periods, potential use of buprenorphine-based medication-assisted treatment, and extended residential or intensive outpatient programming for patients with significant 7-OH dependence.

Overdose Response: Emergency responders and treatment staff should be aware that naloxone (Narcan) can reverse 7-OH overdose, though multiple doses may be necessary. This is a critical education point for harm reduction programs and first responder training.

Navigating Treatment for 7-OH Dependence in New York State

For individuals and families in New York State dealing with 7-OH or kratom dependence, professional guidance is essential. Addiction treatment navigation services can help connect individuals to appropriate levels of care — including medically supervised detox, residential treatment, and intensive outpatient programs — tailored to the specific clinical challenges presented by 7-OH withdrawal.

Resources available for New York State residents include:

• Every1 Center — Addiction treatment navigation serving the Capital Region and Hudson Valley including Albany, Troy, Schenectady, and Saratoga Springs: every1center.com
• Hudson Valley Addiction Treatment Center — Treatment resources for the Hudson Valley region: hvatc.com
• Long Island Addiction Treatment Resources — Treatment navigation for Long Island and the greater New York City area, including specialized kratom addiction treatment resources: longisland.rehab
• Intervention NY — Professional intervention services throughout New York State for families in crisis: interventionny.com

The SAMHSA National Helpline is available 24/7 at 1-800-662-4357 for free, confidential treatment referrals and information.

Conclusion: 7-OH Represents a New Chapter in the Opioid Crisis

The rapid proliferation of concentrated 7-hydroxymitragynine products — from gas station shelves to online retailers — represents one of the most significant emerging substance abuse challenges facing the addiction treatment field in 2026. With opioid receptor binding affinity up to 22 times greater than morphine, confirmed fatal overdoses, surging poison control reports, and an extended withdrawal timeline that complicates treatment, 7-OH demands the attention of every addiction professional, interventionist, and clinical team.

The distinction between natural kratom leaf products and concentrated synthetic 7-OH is not merely academic — it is clinically essential. Treatment professionals who encounter clients reporting kratom use must ask specific questions about product type, brand, concentration, and route of administration to accurately assess risk and plan appropriate interventions.

As federal and state regulatory action continues to unfold in 2026, the addiction treatment community has an obligation to stay informed, educate clients and families, and ensure that treatment protocols evolve to address this potent opioid-like substance with the clinical seriousness it warrants.

References and Sources

1. U.S. Food and Drug Administration. "FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers." FDA Press Release, July 29, 2025. fda.gov
2. Smith KE, Boyer EW, Grundmann O, McCurdy CR, et al. "The rise of novel, semi-synthetic 7-hydroxymitragynine products." Addiction. December 2024. Wiley Online Library
3. Johns Hopkins Medicine. "Emerging Use of Kratom in US: Kratom Use Disorder Experts Propose Decision-Making Algorithm for Clinicians." February 2025. hopkinsmedicine.org
4. Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. "Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine." Addiction Biology. 2019;24:874–885. PubMed
5. Los Angeles County Department of Public Health. "Fatal Overdoses Associated with 7-Hydroxymitragynine (7-OH) in Los Angeles County." Health Alert, September 12, 2025. lacounty.gov
6. Texas Department of State Health Services. "Serious Illnesses Associated with 7-OH Use." August 2025. dshs.texas.gov
7. Washington Poison Center. "Kratom and 7-hydroxymitragynine poisoning." 2025. wapc.org
8. Venable LLP. "FDA Announces Plan to Restrict 7-OH Opioid Products." Legal Analysis, August 2025. venable.com
9. University of Illinois at Chicago College of Pharmacy. "Buprenorphine and buprenorphine-naloxone for the treatment of kratom withdrawal." Drug Information Group FAQ, August 2023. uic.edu
10. Rockefeller Institute of Government. "On Kratom, or The Fractured Regulation of Unscheduled Drugs." October 2025. rockinst.org
11. Bruijnzeel AW, et al. "Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats." Psychopharmacology. 2020;237(10):3025–3037. PMC
12. WUSF News. "Challenge issued against Florida's ban on smoke shop product 7-OH." November 13, 2025. wusf.org

About the Author

Benjamin Zohar, NCACIP, is a Nationally Certified Advanced Clinical Intervention Professional and ISSUP moderator with over a decade of experience in addiction treatment navigation and crisis intervention. He operates a network of treatment navigation and placement services across New York State, including Every1 Center, Hudson Valley Addiction Treatment Center, Long Island Addiction Treatment Resources, and Intervention NY. His work bridges clinical expertise with accessible public education on complex substance use and policy topics.

Medical Reviewer: Brandon McNally, RN, provides clinical accuracy review for all published content.

Editorial Support: Ezra Zohar, M.S. Ed.

This article is intended for educational and informational purposes for addiction professionals and the general public. It does not constitute medical advice. Individuals concerned about 7-OH use, kratom dependence, or substance use disorders should consult with qualified healthcare professionals or contact the SAMHSA National Helpline at 1-800-662-4357.